Pacritinib
Details of the Drug
- Generic Name:
- Pacritinib
- Drug Type:
- Kinase inhibitor
- How the Drug is Given:
Capsules, for oral use
- Names:
- Vonjo™
- Pacritinib
Indications and Usage
Pacritinib is indicated for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 109/L.
This indication is approved under accelerated approval based on spleen volume reduction. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
Side effects needing medical attention
The most common adverse reactions are diarrhea, thrombocytopenia, nausea, anemia, and peripheral edema.
For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.